US McCarter & English has recruited IP lawyers John Gutkoski and Jonathan Lovely as partners in its Boston office.
Gutkoski’s patent and IP practice is rooted in life sciences and technology cases, having advised on matters involving pharmaceuticals, medical devices and nanotechnology.
He won a complete defence jury verdict of non-infringement and invalidity for Palomar Medical in the Eastern District of Texas in a dispute over patents concerning the interaction of light and human tissue, as well as serving as lead counsel for Reckitt Benckiser in a multi-patent Hatch Waxman litigation involving its drug Mucinex in the District Court for the District of Delaware. He was also lead counsel for Molecular Insight Pharmaceuticals in a case that went before the District of Massachusetts and involved EU patent development rights.
“McCarter is one of the fastest growing IP groups here in Boston, particularly in terms of life sciences,” Gutkoski told PLN. “The group that they have put together here in pharmaceutical and biotech sciences has become and continues to be one of the pre-eminent IP practices in the city.”
“This was a wonderful opportunity to join that platform and continue the trial work I’ve been doing with a great group of individuals,” he added.
Before formally starting at McCarter in early October, Gutkoski practised at Barclay Damon. Prior to this, he was the IP chairman at Foley & Lardner’s Boston office.
Jonathan Lovely focuses on cases involving healthcare devices and life sciences.
He has prepared and prosecuted patents in several technology areas, including medical, dental and mechanical devices, and has counselled both multinational corporations and small start-ups. “As a patent prosecutor, I have had the opportunity to work on a number of important and interesting life science and MedTech cases,” he told PLN.
Lovely is a trained engineer, having worked for pharmaceutical company Acusphere for five years as a senior process development and formulation engineer.
He joined Sunstein Kann Murphy & Timbers as a patent attorney in 2005, before becoming a partner there in 2015.
“McCarter has a great reputation both in and out of the IP space,” Lovely said. “From an IP and patent perspective, the IP group has expertise in every technology area. This is becoming increasingly important as technology evolves and products and inventions incorporate varying technology disputes.”
“We are excited to add John and Jonathan to our IP strategies platform,” McCarter’s IP leader Betty Hanley said in a statement. “They are a terrific fit with our team and align beautifully with the needs of our life science, medical device and high technology client base.”
“With John and Jonathan added to the mix, we continue to position our service around our clients’ needs and objectives,” she added.
Neither Barclay Damon nor Sunstein replied to PLN’s request for comment.